Booming Celltrion Falls After FDA Warning Letter
Celltrion are down more than 5 percent after the company announced it received a warning letter from the FDA after the regulatory agency inspected a company drug manufacturing facility. Source:…
Lilly Exploring Strategic Alternatives for Animal Health Biz
Sluggish growth is the main driver for the decision.. Source: BioSpace
Investors Elated as Vertex Picks Two Top CF Triple Combos for Phase III Trials
Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy. Source: BioSpace
Cambridge's AVROBIO Lands $60M to Push Fabry, Rest of Pipeline Into the Clinic
The company plans to initiate a Phase 2 clinical trial this year with AVR-RD-01 in Fabry disease. Source: BioSpace
Stada Names Novartis Exec as New CEO, It's Fifth Leader Since 2016
Today STADA announced the appointment of Peter Goldschmidt as new CEO and chairman of the board. Source: BioSpace
Voyager Founder and CEO to Step Down, Hunt for New Leader Begins
Dr. Paul has been with the company for six years since its inception, initially as president of R&D, Source: BioSpace
Despite Spike, Why Investors Should Still Avoid MannKind Like the Plague
MannKind could be sent to dilute shares in a significant manner, warns Maxim analyst Jason Kolbert in a research note released today. Source: BioSpace
SoCal's Vical Terminates 54% of Workforce to Focus Resources on Two Clinical Programs
Vical announced its restructuring late Tuesday. Source: BioSpace
3 Cases of Brain Damage Force the FDA to Slap a Hold on Bellicum's Lead Drug
The company is now waiting for the FDA to determine a path forward in resuming clinical studies. Source: BioSpace
Trump Endorses 'Right to Try' Experimental Drug Bill at State of the Union Address
The bill would allow access to experimental treatments for patients with terminal conditions. Source: BioSpace
- Go to the previous page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- …
- 288
- Go to the next page